BRAF and non-small cell lung carcinoma: Further validation in the cohort B analysis also revealed similar ORR, PFS, and OS in both BRAF V600E and Non-V600E subgroups of NSCLC patients following treatment with ICIs monotherapy and combined with ICIs.